In preliminary data, the test has demonstrated ‘promising’ specificity and sensitivity in detecting early-stage colorectal cancer. Credit: Jo Panuwat D/Shutterstock

Mainz Biomed has announced a partnership with Quest Diagnostics to support the commercialisation of its NextGen colorectal cancer screening test, ColoAlert.

The test leverages polymerase chain reaction (PCR) technology to detect cancerous DNA in stool samples and is poised to enhance early detection of this malignancy.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In preliminary data, the test has demonstrated ‘promising’ specificity and sensitivity in detecting early-stage colorectal cancer and advanced adenomas.

Quest Diagnostics will facilitate clinical trial laboratory services for Mainz Biomed’s ReconAAsense study, which aims to enrol nearly 15,000 individuals from 150 sites across the US. It is a prospective clinical trial designed to provide data supporting the Food and Drug Administration (FDA) validation of the test.

Additionally, Mainz Biomed will grant Quest the option to exercise semi-exclusive rights to offer testing services based on the ColoAlert test kit, contingent upon FDA approval, for a duration of 18 months.

Mainz Biomed CEO Guido Baechler said: “We are excited by the opportunity to work with Quest Diagnostics.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Quest is a leader in cancer diagnostics and knows how to scale these innovations to make them broadly accessible to patients in need. With their support, we are positioned to advance commercial development of our ColoAlert test in order to help more patients gain access to quality screening.”

The non-invasive test is already marketed across Europe and the United Arab Emirates.

In May 2023, the company entered a commercial partnership with TESTDNA to distribute ColoAlert in Poland.

Colorectal cancer is the third most common cancer worldwide. The US Preventive Services Task Force recommends regular screening starting at age 45.